Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1517 Articles

Chris Lange | Jan 3, 2018 at 10:45 AM EST

Sangamo Jumps on Newest Pfizer Collaboration

Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with…

Jon C. Ogg | Jan 3, 2018 at 8:35 AM EST

2018 Bull/Bear Outlook: How All 30 DJIA Stocks Will Take the Market to 26,400 or Higher

Here is a consensus forecast of each of the 30 Dow Jones Industrial stocks, including a forward 12-month consensus analyst…

Chris Lange | Dec 28, 2017 at 10:25 AM EST

More and More Short Sellers Raising the Stakes in Major Pharma

The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Jon C. Ogg | Dec 26, 2017 at 11:15 AM EST

Meet the Preliminary Dogs of the Dow for 2018

One strategy that has been popular each year as investors rebalance and make changes is the so-called Dogs of the…

Paul Ausick | Dec 20, 2017 at 4:01 PM EST

Disney, General Electric Hobble DJIA on Wednesday

Disney, Pfizer, General Electric, and McDonald's weighed on the DJIA Wednesday.

Jon C. Ogg | Dec 18, 2017 at 12:30 PM EST

Tax Reform Stocking Stuffer: Pfizer Dividend Hike & Much Larger Stock Buyback

Pfizer has just raised its payout by about 6% and more than doubled what it already had on its buyback…

Paul Ausick | Dec 15, 2017 at 4:01 PM EST

Intel, Microsoft Dominate DJIA Friday

Intel, Microsoft, Pfizer, and United Technologies drove the DJIA higher Friday.

Trey Thoelcke | Dec 15, 2017 at 7:20 AM EST

Pfizer Headed for New High After FDA Nod for Joint Disease Treatment

Shares of Pfizer appeared to be headed for a new high after the company announced that the FDA had approved…

Chris Lange | Dec 13, 2017 at 11:05 AM EST

Why Cellectis Is Winning Big With Its Pfizer Partnership

Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two…

Chris Lange | Dec 12, 2017 at 10:40 AM EST

Short Sellers Can’t Make Up Their Minds on Major Pharma

The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Paul Ausick | Dec 11, 2017 at 4:01 PM EST

Disney, Apple Pace Dow to Monday Gain

Apple, Disney, Merck, and Pfizer were the leading gainers among the Dow 30 stocks on Monday. Bitcoin settled up 23%…

Jon C. Ogg | Dec 11, 2017 at 1:15 PM EST

Will Consumers Trust Generic Viagra?

A generic version of Viagra is coming to America, but will existing customers be willing to switch over to a…

Jon C. Ogg | Dec 6, 2017 at 10:05 AM EST

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately,…

Paul Ausick | Dec 5, 2017 at 4:01 PM EST

Disney, Intel Sink DJIA on Tuesday

Disney, Intel, Pfizer, and Verizon led Tuesday's drop in the DJIA.

Lee Jackson | Nov 30, 2017 at 10:00 AM EST

Merrill Lynch Bullish on Deep Value Pharmaceuticals: 5 Stocks to Buy for 2018

One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be…

1 … 39 40 41 42 43 … 102

Pfizer : PFE

All Pfizer Articles

Sangamo Jumps on Newest Pfizer Collaboration

2018 Bull/Bear Outlook: How All 30 DJIA Stocks Will Take the Market to 26,400 or Higher

More and More Short Sellers Raising the Stakes in Major Pharma

Meet the Preliminary Dogs of the Dow for 2018

Disney, General Electric Hobble DJIA on Wednesday

Tax Reform Stocking Stuffer: Pfizer Dividend Hike & Much Larger Stock Buyback

Intel, Microsoft Dominate DJIA Friday

Pfizer Headed for New High After FDA Nod for Joint Disease Treatment

Why Cellectis Is Winning Big With Its Pfizer Partnership

Short Sellers Can’t Make Up Their Minds on Major Pharma

Disney, Apple Pace Dow to Monday Gain

Will Consumers Trust Generic Viagra?

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

Disney, Intel Sink DJIA on Tuesday

Merrill Lynch Bullish on Deep Value Pharmaceuticals: 5 Stocks to Buy for 2018

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

AI Architect Earning $1.1M/Year Almost Took on $550K in Debt to Dodge Taxes: ‘I Have No Idea What That Business Is’

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

Pfizer : PFE

All Pfizer Articles

Sangamo Jumps on Newest Pfizer Collaboration

2018 Bull/Bear Outlook: How All 30 DJIA Stocks Will Take the Market to 26,400 or Higher

More and More Short Sellers Raising the Stakes in Major Pharma

Meet the Preliminary Dogs of the Dow for 2018

Disney, General Electric Hobble DJIA on Wednesday

Tax Reform Stocking Stuffer: Pfizer Dividend Hike & Much Larger Stock Buyback

Intel, Microsoft Dominate DJIA Friday

Pfizer Headed for New High After FDA Nod for Joint Disease Treatment

Why Cellectis Is Winning Big With Its Pfizer Partnership

Short Sellers Can’t Make Up Their Minds on Major Pharma

Disney, Apple Pace Dow to Monday Gain

Will Consumers Trust Generic Viagra?

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

Disney, Intel Sink DJIA on Tuesday

Merrill Lynch Bullish on Deep Value Pharmaceuticals: 5 Stocks to Buy for 2018

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

AI Architect Earning $1.1M/Year Almost Took on $550K in Debt to Dodge Taxes: ‘I Have No Idea What That Business Is’

Featured Reads

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account